Drug Approval | October 21, 2021
U.S. FDA gives green light to Moderna and J&J booster doses
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
U.S. FDA to decide whether to authorize a booster dose in the coming days
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Subscribe To Our Newsletter & Stay Updated
